Foralumab clinical trials
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses foralumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Tiziana Life Sciences LTD (5) · Light Chain Bioscience - Novimmune SA (2)
Studies
Open first, then newest update. How each study uses foralumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsActive, not recruitingPhase 2Tiziana Life Sciences LTDNCT06292923Written as Foralumab
- A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's DiseaseWithdrawnPhase 1Tiziana Life Sciences LTDNCT05028946Written as Foralumab
- In-patient COVID-19 Study of Intranasal ForalumabWithdrawnPhase 2Tiziana Life Sciences LTDNCT04983446Written as Foralumab
- Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MSWithdrawnPhase 1Tiziana Life Sciences LTDNCT05029609Written as Intranasal Foralumab Solution
- Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DMWithdrawnPhase 2Tiziana Life Sciences LTDNCT03291249Written as Foralumab
- NI-0401 in Patients With Acute Renal Allograft RejectionCompletedPhase 1/2Light Chain Bioscience - Novimmune SANCT00805909Written as NI-0401
- NI-0401 in Active Crohn's DiseaseCompletedPhase 1/2Light Chain Bioscience - Novimmune SANCT00630643Written as NI-0401 (anti-CD3 mAB)
Codes
What other systems call foralumab · ClinicalTrials.gg INT000855
- MeSH (NLM) C000625403foralumabOne source NLM
- UNII (FDA) J43DL56H6MFORALUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5467179ForalumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95785ForalumabOne source FDA
- DrugBank DB16170One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625403 | foralumab | One source NLM |
| UNII (FDA) | J43DL56H6M | FORALUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5467179 | Foralumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95785 | Foralumab | One source FDA |
| DrugBank | DB16170 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.